GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Cardio Diagnostics
Cardio Diagnostics is a company developing AI-based diagnostic tests for detecting cardiovascular diseases. Its stock price is a bet on a breakthrough in early diagnostics. The chart reflects investor expectations for its technology.
Share prices of companies in the market segment - Medanalysis
Cardio Diagnostics is a biotech company that uses DNA analysis and artificial intelligence for the early detection of cardiovascular diseases. We've categorized it as a "Medanalysis" company. The chart below shows how investors value companies in the predictive cardiac diagnostics sector.
Broad Market Index - GURU.Markets
Cardio Diagnostics is a medical diagnostics company that uses artificial intelligence to analyze genetic data for the early detection of cardiovascular disease. It is a component of the GURU.Markets index. The chart below represents the market. See how this stock compares to the biotech sector.
Change in the price of a company, segment, and market as a whole per day
CDIO - Daily change in the company's share price Cardio Diagnostics
Cardio Diagnostics Holdings' daily share price fluctuations reflect the volatility of the medical diagnostics sector. The metric demonstrates sensitivity to news about the introduction of its cardiovascular risk assessment tests.
Daily change in the price of a set of shares in a market segment - Medanalysis
Cardio Diagnostics develops AI-powered diagnostic tests for the early detection of cardiovascular diseases. Medtech and AI are two highly dynamic sectors. The chart below shows the average volatility in this industry, helping to assess the dynamics of Cardio Diagnostics.
Daily change in the price of a broad market stock, index - GURU.Markets
Cardio Diagnostics uses artificial intelligence for the early diagnosis of cardiovascular diseases. This medtech company's stock reflects the growing role of AI in medicine. Its volatility is part of the dynamics of the innovation sector, which influences the entire market.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Cardio Diagnostics
For Cardio Diagnostics Holdings, year-over-year performance is a story of the adoption of its tests for the early detection of cardiovascular disease. Its market capitalization growth over the past 12 months reflects its success in commercializing its AI- and genetic-based tests. Each new contract with a laboratory or insurance company is a fundamental step.
Annual dynamics of market capitalization of the market segment - Medanalysis
Cardio Diagnostics, a company using AI to analyze cardiac diseases, is betting on medical innovation. Its performance relative to the sector will reveal how much investors believe in its ability to commercialize its unique technology and secure regulatory approval.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Cardio Diagnostics, a company using artificial intelligence for early detection of cardiovascular diseases, is at the intersection of medicine and technology. Its year-over-year market capitalization reflects investors' belief that its algorithms can predict risks better than traditional methods, opening up a huge market.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Cardio Diagnostics
Cardio Diagnostics is a biotech company using AI to diagnose heart disease. Its monthly performance reflects progress in commercializing its tests. News of clinical partnerships and data confirming the accuracy of its technology are key.
Monthly dynamics of market capitalization of the market segment - Medanalysis
Cardio Diagnostics is a company developing tests based on artificial intelligence and genetics for the early diagnosis of cardiovascular diseases. Success depends on the accuracy of these tests and their implementation in clinical practice. The dynamics of the medical diagnostics sector reflect the overall trend toward preventive and personalized medicine, which is a tailwind for Cardio Diagnostics.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Cardio Diagnostics develops AI-based tests for the early diagnosis of cardiovascular diseases. This is a promising area of medical technology. The company's stock performance is weakly correlated with the market and is driven by the success of its tests' commercialization and the results of clinical trials confirming their effectiveness.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Cardio Diagnostics
Cardio Diagnostics develops AI-based diagnostic tests for cardiovascular disease detection. Its weekly stock price reflects news about clinical validation of its tests, partnerships with clinics, and insurance company coverage decisions.
Weekly dynamics of market capitalization of the market segment - Medanalysis
Cardio Diagnostics develops genetic tests for the early detection of cardiovascular diseases. This is a promising niche in preventive medicine. The chart will show how investors view its potential and how its weekly performance compares to the average for the medical diagnostics sector.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Cardio Diagnostics develops genetic tests for detecting heart disease. Its shares are a bet on the success of its medical technologies. The chart clearly shows how its performance is detached from the broader market and driven by news about the introduction of its tests.
Market capitalization of the company, segment and market as a whole
CDIO - Market capitalization of the company Cardio Diagnostics
Cardio Diagnostics' market capitalization reflects investors' bets on its genetic tests for cardiovascular disease. Its performance reflects the market's belief that its epigenetics- and AI-based approach will more accurately predict risks. Its low valuation reflects its enormous potential, coupled with the high risk of commercialization.
CDIO - Share of the company's market capitalization Cardio Diagnostics within the market segment - Medanalysis
Cardio Diagnostics develops genetic tests for the early diagnosis of cardiovascular disease. Its market share in the medical technology sector is small, but it is an innovator in preventive cardiology. Its capitalization is a bet on its AI platform, which can personalize risk assessment.
Market capitalization of the market segment - Medanalysis
This graph shows the total market capitalization of the entire medical diagnostics market. For Cardio Diagnostics, with its AI-based tests for detecting heart disease, this line is a map of the future of cardiology. The rising graph reflects the trend toward personalized and predictive medicine, where the company is seeking to carve out its niche.
Market capitalization of all companies included in a broad market index - GURU.Markets
Cardio Diagnostics develops diagnostic tests based on genetics and AI for the early detection of cardiovascular diseases. Its market capitalization is based on the preventive cardiology market. This represents the share of the overall market occupied by the heart attack prediction and prevention business.
Book value capitalization of the company, segment and market as a whole
CDIO - Book value capitalization of the company Cardio Diagnostics
Cardio Diagnostics develops AI-based diagnostic tests for the early detection of cardiovascular diseases. Its book value is its scientific and financial capital. It consists of funds for R&D and the commercialization of its tests. How has this capital changed? The chart below shows.
CDIO - Share of the company's book capitalization Cardio Diagnostics within the market segment - Medanalysis
Cardio Diagnostics is a medical diagnostics company. Its AI- and genetic-based tests require physical infrastructure: certified laboratories to conduct the tests and IT infrastructure to run the algorithms. The chart shows its share of the physical assets that underpin precision medicine.
Market segment balance sheet capitalization - Medanalysis
Cardio Diagnostics is a diagnostics company. Compared to the capital-intensive healthcare sector, its model is knowledge-intensive. The industry's asset chart reflects the value of hospitals. Cardio, on the other hand, invests in laboratories and AI to develop its tests.
Book value of all companies included in the broad market index - GURU.Markets
Cardio Diagnostics' assets are not clinics, but a laboratory and an AI platform for epigenetic testing, enabling early detection of cardiovascular disease risk. The book value reflects the material base for this innovative predictive diagnostic. The chart shows its scale.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Cardio Diagnostics
Cardio Diagnostics is a medical technology company using AI for the early diagnosis of cardiovascular diseases. Its market value is determined by its unique algorithms and their life-saving potential, which is valued far above its tangible assets.
Market to book capitalization ratio in a market segment - Medanalysis
Cardio Diagnostics develops genetic tests for the early detection of cardiovascular diseases. Its value lies in its unique technology. The chart shows the high premium investors are paying for its potential to transform approaches to heart disease diagnosis and prevention.
Market to book capitalization ratio for the market as a whole
Cardio Diagnostics develops AI-powered diagnostic tests for cardiovascular diseases. The company's value lies in its algorithms and the accuracy of its analyses. This chart illustrates the significant premium investors are willing to pay for technologies capable of predicting and preventing serious diseases.
Debts of the company, segment and market as a whole
CDIO - Company debts Cardio Diagnostics
Cardio Diagnostics develops AI-based diagnostic tests for the early detection of cardiovascular diseases. The company is raising capital to finance clinical validation studies and commercialization. This chart shows the investment required to bring this new breakthrough medical technology to market.
Market segment debts - Medanalysis
Cardio Diagnostics is a medical technology company developing genetic tests for the early detection and risk assessment of cardiovascular disease. This chart shows how the company, which operates at the intersection of genetics and cardiology, is funding its clinical research and commercialization to make its tests accessible to doctors and patients.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Cardio Diagnostics
Cardio Diagnostics develops genetic tests for the early diagnosis and prevention of cardiovascular diseases. Commercializing such innovative medical tests requires significant investment in clinical research and marketing. This chart shows how the company is using debt to finance its entry into the cardiac diagnostics market.
Market segment debt to market segment book capitalization - Medanalysis
Cardio Diagnostics develops genetic tests for the early detection of cardiovascular diseases. This is an important area, but one that requires investment. This chart shows how the company is funding its research and commercialization. It compares its debt to the market capitalization of the entire medical diagnostics sector, reflecting its financial strategy.
Debt to book value of all companies in the market
Cardio Diagnostics develops genetic tests for early diagnosis and cardiovascular risk assessment. Medical diagnostics is a knowledge-intensive industry that requires investment in research. How dependent is the company on debt? This chart of total market debt provides context for assessing its financial strategy as it moves toward commercialization.
P/E of the company, segment and market as a whole
P/E - Cardio Diagnostics
Cardio Diagnostics is a biotech company developing AI-based diagnostic tests for the early detection of cardiovascular diseases. This chart shows how investors view its innovative approach. The evaluation depends on clinical validation and acceptance of its tests by the medical community.
P/E of the market segment - Medanalysis
Cardio Diagnostics is a biotech company developing AI-based diagnostic tests for the early detection and risk assessment of cardiovascular disease. This chart illustrates the average valuation in the medical diagnostics sector, where investors highly value the potential of predictive medicine to prevent serious illnesses.
P/E of the market as a whole
Cardio Diagnostics is a biotech company that uses artificial intelligence and genetic testing for the early diagnosis and prevention of cardiovascular disease. This chart reflects overall investor interest in the healthcare sector. It helps understand whether Cardio Diagnostics' valuation reflects faith in the future of personalized medicine or general market trends.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Cardio Diagnostics
Cardio Diagnostics develops diagnostic tests based on artificial intelligence and genetics for the early detection of cardiovascular diseases. The company's future depends on the implementation of its tests in clinical practice. This chart reflects investors' confidence in the potential of predictive medicine and the company's ability to transform approaches to heart disease diagnosis.
%20P%2FE%20Cardio%20Diagnostics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Cardio-Diagnostics&v=1772538753131 "Chart of the company's future (projected) P/E Cardio Diagnostics")
Future (projected) P/E of the market segment - Medanalysis
Cardio Diagnostics develops AI-based diagnostic tests for the early detection of cardiovascular diseases. The chart shows average profitability expectations in the sector, helping to understand how the market values the potential of its technology to transform approaches to cardiac diagnosis.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Medanalysis&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Medanalysis&v=1772538753184 "Future (projected) P/E graph of the market segment - Medanalysis")
Future (projected) P/E of the market as a whole
Cardio Diagnostics develops AI-based diagnostic tests for the early detection of cardiovascular diseases. This is a cutting-edge approach in preventive cardiology. This risk appetite chart shows how willing investors are to invest in technologies that could change the paradigm of diagnosis and treatment for the most common diseases.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772538753242 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Cardio Diagnostics
Cardio Diagnostics is a biotech company developing tests based on genetics and artificial intelligence for the early detection and risk assessment of cardiovascular disease. Profit depends on the commercialization of these tests. This chart shows the financial trajectory of the company, which aims to change the approach to heart disease diagnosis.
Profit of companies in the market segment - Medanalysis
Cardio Diagnostics is a biotech company that uses artificial intelligence and genetic data analysis for early detection and risk assessment of cardiovascular disease. This chart shows the overall profitability of the medical analytics sector, where predictive diagnostics and personalized risk assessment are at the forefront of modern medicine.
Overall market profit
Cardio Diagnostics develops AI-based diagnostic tests for the early detection of cardiovascular diseases. The need for such diagnostics is enormous and is not dependent on the economic situation. The company's growth is driven by the implementation of its technology in clinical practice. The dynamics in this chart do not affect its core business.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Cardio Diagnostics
Cardio Diagnostics develops AI-based diagnostic tests for the early detection of cardiovascular diseases. Future profits depend on the commercialization of its technology and acceptance by the medical community. This chart shows analysts' expectations regarding the potential of its innovative approaches in cardiology.
%20profit%20of%20the%20company%20Cardio%20Diagnostics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Cardio-Diagnostics&v=1772538753468 "Graph of future (projected) profit of the company Cardio Diagnostics")
Future (predicted) profit of companies in the market segment - Medanalysis
Cardio Diagnostics is a biotech company that uses artificial intelligence and genetic analysis for the early diagnosis of cardiovascular disease. Its goal is to make cardiac diagnostics more accurate and personalized. This graph shows revenue expectations for the medical diagnostics sector, helping to assess the potential of Cardio Diagnostics' technology.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Medanalysis&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Medanalysis&v=1772538753633 "Graph of future (predicted) profits of companies in a market segment - Medanalysis")
Future (predicted) profit of the market as a whole
Cardio Diagnostics develops AI-based diagnostic tests for the early detection of cardiovascular diseases. Demand for its products depends on healthcare spending. This economic outlook influences healthcare budgets and their focus on preventative medicine.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772538753671 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Cardio Diagnostics
Cardio Diagnostics is a company developing AI-powered diagnostic tests for the early detection of cardiovascular diseases. Revenue growth reflects the adoption of its innovative tests. This chart shows the premium investors are paying for its potential to transform cardiac diagnostics.
P/S market segment - Medanalysis
Cardio Diagnostics is a biotech company that uses artificial intelligence and genetic analysis to develop tests for the early detection and risk assessment of cardiovascular disease, the leading cause of death worldwide. This chart reflects the average revenue estimate for the sector, helping to assess the potential of their innovative diagnostic platform.
P/S of the market as a whole
Cardio Diagnostics develops AI-based diagnostic tests for the early detection and risk assessment of cardiovascular diseases. This chart highlights that the valuation of such MedTech companies is based on the potential of their technologies to prevent serious diseases, which the market can value at a significant premium.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Cardio Diagnostics
Cardio Diagnostics is a biotech company that uses artificial intelligence and genetic analysis for the early diagnosis of cardiovascular disease. For such an innovative company, the company's future revenue valuation is critical. It reflects investors' belief that its tests will become standard medical practice, opening a huge market for its diagnostic solutions.
%20P%2FS%20Cardio%20Diagnostics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Cardio-Diagnostics&v=1772538753990 "The graph of the company's future (projected) P/S Cardio Diagnostics")
Future (projected) P/S of the market segment - Medanalysis
Cardio Diagnostics is a biotech company using artificial intelligence and genetic testing for early diagnosis and cardiovascular risk assessment. This chart compares the company's estimated future sales with expectations for the medical diagnostics sector. It shows whether investors believe its predictive tests will become a significant tool in cardiology.
%20P%2FS%20market%20segment%20graph%20-%20Medanalysis&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Medanalysis&v=1772538754055 "Future (projected) P/S market segment graph - Medanalysis")
Future (projected) P/S of the market as a whole
Cardio Diagnostics develops diagnostic tests based on artificial intelligence and genetics for the early detection of cardiovascular diseases. The company's growth depends on the implementation of its tests in clinical practice. This graph of investor expectations reflects their belief that preventive and personalized medicine is the future of healthcare.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772538754082 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Cardio Diagnostics
For Cardio Diagnostics, this figure reflects revenue from its innovative AI-based tests for the early detection of cardiovascular diseases. Revenue growth depends on the adoption of these tests in clinical practice and their acceptance by physicians and insurance companies as an effective preventative medicine tool.
Sales of companies in the market segment - Medanalysis
Cardio Diagnostics is a biotech company that uses artificial intelligence and genetic testing for the early detection of cardiovascular disease. As it commercializes, its revenue structure will reflect revenue from sales of its diagnostic tests, reflecting its innovative approach to heart disease prevention.
Overall market sales
Cardio Diagnostics develops genetic tests for the early detection and risk assessment of cardiovascular disease. The company is at the forefront of preventative medicine. This general economic climate doesn't diminish the fundamental need for more accurate, life-saving diagnostics, making the company's mission relevant in any economic environment.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Cardio Diagnostics
Cardio Diagnostics is a biotech company developing genetic tests for early diagnosis and cardiovascular risk assessment. Revenue growth depends on the adoption of its tests in clinical practice. This chart shows analysts' forecasts for demand for personalized approaches in cardiology and the commercialization of its diagnostic products.
%20sales%20of%20the%20company%20Cardio%20Diagnostics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Cardio-Diagnostics&v=1772538754182 "Schedule of future (projected) sales of the company Cardio Diagnostics")
Future (projected) sales of companies in the market segment - Medanalysis
Cardio Diagnostics develops genetic tests for the early detection and risk assessment of cardiovascular disease. This chart illustrates the forecast for the medical testing market. Is the demand for personalized and predictive diagnostics for disease prevention growing? This determines the overall outlook for the industry.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Medanalysis&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Medanalysis&v=1772538754199 "Schedule of future (projected) sales of companies in the market segment - Medanalysis")
Future (projected) sales of the market as a whole
Cardio Diagnostics is a medical company specializing in tests for the early detection of cardiovascular diseases. Demand for such diagnostics is driven by healthcare systems and the push for preventative medicine. This timeline is of minimal significance, as heart disease is the leading cause of death, and its early detection is a priority in any economy.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772538754221 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Cardio Diagnostics
Cardio Diagnostics develops diagnostic tests based on artificial intelligence and genetics for the early detection of cardiovascular diseases. This chart shows the company's financial trajectory during the commercialization phase. Profitability depends on the acceptance of its tests by the medical community, obtaining insurance coverage, and demonstrating their clinical and cost-effectiveness.
Market segment marginality - Medanalysis
Cardio Diagnostics, Inc. develops artificial intelligence-based diagnostic tests for the early detection of cardiovascular diseases. This chart reflects the company's financial performance at the commercialization stage, where profitability depends on the clinical adoption of its tests and reimbursement from insurance companies.
Market marginality as a whole
Cardio Diagnostics develops AI-based diagnostic tests for the early detection of cardiovascular diseases. Its success depends on the implementation of these technologies in clinical practice. This overall profitability chart reflects the state of the healthcare system and its willingness to invest in preventive medicine.
Employees in the company, segment and market as a whole
Number of employees in the company Cardio Diagnostics
Cardio Diagnostics is a biotech company developing AI-based tests for the early detection of cardiovascular diseases. Its team of scientists and data scientists is its greatest asset. This chart shows how the company is expanding its staff to validate its tests and prepare for their commercial launch.
Share of the company's employees Cardio Diagnostics within the market segment - Medanalysis
Cardio Diagnostics develops AI-based diagnostic tests for the early detection of cardiovascular diseases. This approach requires a team of bioinformaticians, geneticists, and machine learning specialists. This graph shows the company's market share, reflecting its scientific potential and innovation in medical diagnostics.
Number of employees in the market segment - Medanalysis
Cardio Diagnostics develops diagnostic tests based on artificial intelligence and genetics for the early detection of cardiovascular diseases. This chart shows employment trends in the medical analytics sector. The company's personalized approach allows for assessing heart disease risk based on a patient's unique genetic profile.
Number of employees in the market as a whole
Cardio Diagnostics is a biotech company developing AI-based tests for the early detection of cardiovascular diseases. Its growth depends on the implementation of innovations in medical practice. This chart shows overall employment, and Cardio Diagnostics exemplifies how technology is changing healthcare, creating jobs at the intersection of medicine and IT.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Cardio Diagnostics (CDIO)
Cardio Diagnostics is a medical technology company that uses AI to analyze genetic data and diagnose cardiovascular diseases early. Their main asset is their algorithms. This chart shows the high market value the market attributes to their intellectual property. It reflects the value of their AI R&D per employee.
%20of%20the%20company%20Cardio%20Diagnostics%20(CDIO)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Cardio-Diagnostics-CDIO&v=1772538754494 "Chart of market capitalization per employee (in thousands of dollars) of the company Cardio Diagnostics (CDIO)")
Market capitalization per employee (in thousands of dollars) in the market segment - Medanalysis
Cardio Diagnostics (CDIO) develops AI-based diagnostic tests for the early detection of cardiovascular diseases. In the medtech industry, this metric is an assessment of the predictive power of their technology. The high market capitalization per employee demonstrates the potential of their algorithms to save lives, creating enormous social and economic value.
%20by%20market%20segment%20-%20Medanalysis&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Medanalysis&v=1772538754532 "Market capitalization per employee (in thousands of dollars) by market segment - Medanalysis")
Market capitalization per employee (in thousands of dollars) for the overall market
Cardio Diagnostics is a medical diagnostics company that has developed an AI-based test for the early detection of cardiovascular diseases. The company's value lies in its unique technology. The graph shows a high employee value, as the market sees enormous potential in preventive medicine.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772538754540 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Cardio Diagnostics (CDIO)
Cardio Diagnostics is a company using AI and genetic markers for the early diagnosis of cardiovascular diseases. It's a MedTech R&D company. This chart shows the commercialization stage of their tests. A loss per employee represents investment in R&D, while a profit would indicate successful market entry.
%20Chart%20Cardio%20Diagnostics%20(CDIO)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Cardio-Diagnostics-CDIO&v=1772538754636 "Company Profit Per Employee (in thousands of dollars) Chart Cardio Diagnostics (CDIO)")
Profit per employee (in thousands of dollars) in the market segment - Medanalysis
Cardio Diagnostics, Inc. is a biotech company developing AI-based tests for the early detection of cardiovascular diseases. In the field of predictive medicine, efficiency per employee reflects the value of their algorithms. This chart shows the financial return each specialist generates, a key metric in the sector.
%20in%20the%20market%20segment%20-%20Medanalysis&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Medanalysis&v=1772538754780 "Chart of profit per employee (in thousands of dollars) in the market segment - Medanalysis")
Profit per employee (in thousands of dollars) for the market as a whole
Cardio Diagnostics is a medical technology company using AI and genetics for the early diagnosis of cardiovascular diseases. It is a B2B business providing laboratory diagnostic services. This chart shows how a sector where value is created by R&D and laboratory technologies compares in terms of personnel efficiency compared to a market dominated by other models.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772538754869 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Cardio Diagnostics (CDIO)
Cardio Diagnostics is developing AI-based diagnostic tests for cardiovascular disease detection. This chart demonstrates the commercial success of their innovative approach. Increasing revenue per employee will mean widespread adoption of their tests, enabling the monetization of their cutting-edge scientific research.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Cardio-Diagnostics-CDIO&v=1772538754985 "Sales chart per company employee Cardio Diagnostics (CDIO)")
Sales per employee in the market segment - Medanalysis
Cardio Diagnostics (CDIO) is a medical technology company developing diagnostic tests (based on epigenetics and AI) for the early detection of cardiovascular diseases. This chart shows the average output in the sector. For CDIO, this is an indicator of how productive their R&D and commercial teams are in advancing these innovative tests.
Sales per employee for the market as a whole
Cardio Diagnostics uses AI and genetic analysis to develop diagnostic tests for cardiovascular diseases. Their business consists of R&D and laboratory services. This indicator demonstrates how effective their science-based model is in converting tests into commercial revenue.
Short shares by company, segment and market as a whole
Shares shorted by company Cardio Diagnostics (CDIO)
Cardio Diagnostics (CDIO) develops genetic tests for the early detection of cardiovascular disease. This chart shows the number of short positions. These short positions may reflect doubts about the company's tests being accepted by the medical community and insurance companies as a new diagnostic standard.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Cardio-Diagnostics-CDIO&v=1772538755319 "Short Shares Chart for the Company Cardio Diagnostics (CDIO)")
Shares shorted by market segment - Medanalysis
Cardio Diagnostics (CDIO) is a biotech company developing epigenetics-based diagnostic tests (DNA analysis) for the early detection of cardiovascular diseases. This chart shows the total short position in the medical diagnostics sector, reflecting investor skepticism about the commercialization of these new tests.
Shares shorted by the overall market
Cardio Diagnostics develops AI tests for diagnosing heart disease. It's a venture-backed R&D company. This chart illustrates the market's overwhelming pessimism. When investors panic, they don't want to fund the "future of medicine." They see a company burning through cash and fear running out of money before the product hits the market.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Cardio Diagnostics (CDIO)
Cardio Diagnostics uses AI to analyze cardiovascular risks. It's a combination of two hot topics. This oscillator reflects the feverish anticipation. It overheats on any news about breakthroughs in their AI models or partnerships with clinics, and then cools down during the long wait for commercialization and approvals.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Cardio-Diagnostics-CDIO&v=1772538755412 "RSI 14 indicator chart for the company's stock Cardio Diagnostics (CDIO)")
RSI 14 Market Segment - Medanalysis
Cardio Diagnostics (CDIO) is a company developing advanced tests (likely AI-powered) for the early diagnosis of cardiovascular disease. It's a highly speculative sector. This chart measures the collective "pulse" of the entire Medical Analysis segment. It helps investors understand whether CDIO's move is a response to their data or whether the entire industry is overheated by the hype surrounding AI in medicine or oversold.
RSI 14 for the overall market
For Cardio Diagnostics, a company that specializes in analytics, this chart is a lifeline showing capital availability. During periods of market euphoria, investors are willing to generously fund risky but promising R&D projects. During periods of panic, the money supply is turned off, and cash-burning companies risk running out of funds.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast CDIO (Cardio Diagnostics)
Cardio Diagnostics is a smart diagnostics company. It uses AI and epigenetics (DNA analysis) to create tests (Epi+Gen CHD) for the early detection of cardiovascular diseases. This chart shows the speculative average price target from analysts, based on their belief in the commercialization of this new technology.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-CDIO-Cardio-Diagnostics&v=1772538755522 "A chart showing analyst consensus forecasts for the expected stock price. CDIO (Cardio Diagnostics)")
The difference between the consensus estimate and the actual stock price CDIO (Cardio Diagnostics)
Cardio Diagnostics – "precision" cardiology. The company uses AI and epigenetics to create tests (Epi+Gen) for the early diagnosis of heart disease. This chart illustrates the analyst community's opinion on the company's future. It measures the distance between the stock price and the target, reflecting their belief in the implementation of this "smart" diagnostic.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-CDIO-Cardio-Diagnostics&v=1772538755578 "A chart showing the difference between the consensus forecast and the actual stock price. CDIO (Cardio Diagnostics)")
Analyst consensus forecast for stock prices by market segment - Medanalysis
Cardio Diagnostics (CDIO) is a biotech company using AI and genetic analysis (Epi+Gen CHD) for early detection of cardiovascular disease risks. This chart shows general expectations for the medical testing sector. It reflects whether experts believe the predictive cardiac diagnostics market will grow.
Analysts' consensus forecast for the overall market share price
Cardio Diagnostics is a healthcare company using AI and genetic testing (epigenetics) for the early diagnosis of cardiovascular disease. This chart shows overall market sentiment. For a CDIO operating in the "defensive" healthcare sector, general optimism is important, but their growth depends more on the acceptance of their tests by insurance companies and doctors.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Cardio Diagnostics
Cardio Diagnostics is a diagnostic detective for the heart. Their specialty is genetic (DNA) and epigenetic (AI) tests, which (they claim) can predict the risk of a heart attack long before it starts. This chart is a pure indicator of their R&D. It reflects their (very risky) path to FDA approval and their (still) speculative commercial potential.
AKIMA Market Segment Index - Medanalysis
Cardio Diagnostics (CDIO) is a MedTech company using AI and epigenetics to predict heart disease. Their tests (Epi+Gen CHD) analyze DNA to assess heart attack risk, expanding diagnostics beyond simple cholesterol levels. This chart shows the average index for the segment, helping investors assess the demand for this smart diagnostic.
The AKIM Index for the overall market
Cardio Diagnostics offers AI-powered epigenetic blood tests for the detection and management of cardiovascular diseases. This chart, which reflects the market average, provides context. It helps us assess how this innovative diagnostic technology stacks up against overall macroeconomic trends.
